Evidence map›Paper›PMID 23108541›Full record

ReviewPhilosophical transactions of the Royal Society of London. Series B, Biological sciences2012

Why do cannabinoid receptors have more than one endogenous ligand?

Vincenzo Di Marzo, Luciano De Petrocellis

Open access · bronzeAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Philosophical transactions of the Royal Society of London. Series B, Biological sciences, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 134 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
134citing papers in PubMed, 1 pooled it
18.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

134 citing papers in PubMed, 1 synthesis or guideline pooled it, 289 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Review
  5. Review
  6. Review
  7. Changes of CB1 Receptor Expression in Tissues of Cocaine-Exposed Eels.Animals : an open access journal from MDPI · 2025
    Article
  8. Article
  9. Review
  10. Review
  11. Review
  12. Cannabis and Cannabinoid Signaling: Research Gaps and Opportunities.The Journal of pharmacology and experimental therapeutics · 2024
    Review
  13. Article
  14. Review
  15. Cannabinoids in Periodontology: Where Are We Now?Antibiotics (Basel, Switzerland) · 2023
    Review
  16. Review
  17. Article
  18. Article
  19. Review
  20. Review

74 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

Vincenzo Di MarzoEndocannabinoid Research Group, Istituto Chimica Biomolecolare, CNR, Via Campi Flegrei 34, Comprensorio Olivetti, 80078 Pozzuoli, NA, Italy. vdimarzo@icb.cnr.it
Luciano De Petrocellis
Istituto di Chimica Biomolecolare · ITIstituto di Cibernetica “Eduardo Caianiello” · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The endocannabinoid system was revealed following the understanding of the mechanism of action of marijuana's major psychotropic principle, Δ(9)-tetrahydrocannabinol, and includes two G-protein-coupled receptors (GPCRs; the cannabinoid CB1 and CB2 receptors), their endogenous ligands (the endocannabinoids, the best studied of which are anandamide and 2-arachidonoylglycerol (2-AG)), and the proteins that regulate the levels and activity of these receptors and ligands. However, other minor lipid metabolites different from, but chemically similar to, anandamide and 2-AG have also been suggested to act as endocannabinoids. Thus, unlike most other GPCRs, cannabinoid receptors appear to have more than one endogenous agonist, and it has been often wondered what could be the physiological meaning of this peculiarity. In 1999, it was proposed that anandamide might also activate other targets, and in particular the transient receptor potential of vanilloid type-1 (TRPV1) channels. Over the last decade, this interaction has been shown to occur both in peripheral tissues and brain, during both physiological and pathological conditions. TRPV1 channels can be activated also by another less abundant endocannabinoid, N-arachidonoyldopamine, but not by 2-AG, and have been proposed by some authors to act as ionotropic endocannabinoid receptors. This article will discuss the latest discoveries on this subject, and discuss, among others, how anandamide and 2-AG differential actions at TRPV1 and cannabinoid receptors contribute to making this signalling system a versatile tool available to organisms to fine-tune homeostasis.

Indexed as

AnimalsArachidonic AcidsBrainCannabinoid Receptor AgonistsEndocannabinoidsGlyceridesHumansLigandsNeuralgiaPain PerceptionPolyunsaturated AlkamidesReceptor, Cannabinoid, CB1Receptor, Cannabinoid, CB2Receptor Cross-TalkSignal TransductionSynaptic TransmissionanandamideArachidonic AcidsCannabinoid Receptor AgonistsEndocannabinoidsGlyceridesglyceryl 2-arachidonateLigandsPolyunsaturated AlkamidesReceptor, Cannabinoid, CB1Receptor, Cannabinoid, CB2TRPV1 protein, humanTRPV Cation Channels

Identifiers

PMID23108541
PMCPMC3481524
OpenAlexW1969953780

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.